327 related articles for article (PubMed ID: 24313462)
1. Phototherapy, psoriasis, and the age of biologics.
Richard EG; Hönigsmann H
Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
[TBL] [Abstract][Full Text] [Related]
2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
3. Combining traditional systemic and biologic therapies for psoriasis.
Heffernan MP
Semin Cutan Med Surg; 2010 Mar; 29(1):67-9. PubMed ID: 20430311
[TBL] [Abstract][Full Text] [Related]
4. Do utilization management controls for phototherapy increase the prescription of biologics?
Simpson GL; Yelverton CB; Rittenberg S; Feldman SR
J Dermatolog Treat; 2006; 17(6):359-61. PubMed ID: 17853310
[TBL] [Abstract][Full Text] [Related]
5. Phototherapy of psoriasis in the era of biologics: still in.
Benáková N
Acta Dermatovenerol Croat; 2011; 19(3):195-205. PubMed ID: 21933648
[TBL] [Abstract][Full Text] [Related]
6. Disease and treatment burden of psoriasis: examining the impact of biologics.
Raval K; Lofland JH; Waters H; Piech CT
J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
[TBL] [Abstract][Full Text] [Related]
7. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
8. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
Christophers E; Segaert S; Milligan G; Molta CT; Boggs R
J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis phototherapy experience from a Lisbon unit: a still valid therapeutic approach in the 21st century.
Carvalho R; Marques-Pinto G; Cardoso J
Cutan Ocul Toxicol; 2013 Mar; 32(1):78-82. PubMed ID: 22250764
[TBL] [Abstract][Full Text] [Related]
10. Emerging trends in combination strategies with phototherapy in advanced psoriasis management.
Sreya R; Nene S; Pathade V; Singh SB; Srivastava S
Inflammopharmacology; 2023 Aug; 31(4):1761-1778. PubMed ID: 37326755
[TBL] [Abstract][Full Text] [Related]
11. Management and costs of severe psoriasis: the role of new biologics.
Feldman SR; Pearce DJ
Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of Psoriasis Treatment.
Armstrong AW; Gordon KB; Menter MA; Wu JJ
Semin Cutan Med Surg; 2018 Feb; 37(2S):S39-S43. PubMed ID: 29614136
[TBL] [Abstract][Full Text] [Related]
13. Narrowband UVB phototherapy in skin conditions beyond psoriasis.
Gambichler T; Breuckmann F; Boms S; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2005 Apr; 52(4):660-70. PubMed ID: 15793518
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
[TBL] [Abstract][Full Text] [Related]
16. Phototherapy for Psoriasis in the Age of Biologics.
Sandoval AGW; Mahajan A; Buzney E
Dermatol Clin; 2024 Jul; 42(3):399-404. PubMed ID: 38796271
[TBL] [Abstract][Full Text] [Related]
17. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
Price J; Bhosle M; Feldman SR; Balkrishnan R
J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
[TBL] [Abstract][Full Text] [Related]
19. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
